Skip to main content

Advertisement

SpringerLink
Log in

Characteristics of BCR–ABL kinase domain point mutations in Chinese imatinib-resistant chronic myeloid leukemia patients

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

To explore the characteristics of BCR–ABL kinase domain point mutations in Chinese chronic myeloid leukemia (CML) patients, a cohort of 127 patients with hematologic or cytogenetic resistance to imatinib are screened by direct sequencing. Mutations are found in 74 patients (58%). More patients with hematologic resistance show mutations compared to patients with cytogenetic resistance (70% vs 44%, p = 0.002), and more patients with acquired resistance present mutations compared to patients with primary resistance (68% vs 48%, p = 0.031). Frequencies of mutations were similar in early chronic phase (ECP), late chronic phase (LCP), accelerated phase, and blast phase (BP) patients (56%, 58%, 50%, and 69%, respectively; p > 0.05). Overall, 25 mutants are found in 21 amino acid sites, and four of them (I418V, E450A, E453L, and E455K) are first reported here. All patients with these four mutants either progress to or reenter the BP. The most frequent mutant is M244V, followed by Y253H, F359C/V/I, G250E, E255K, and T315I. Only seven patients (9%) have T315I mutants, and all showed hematologic resistance. Three of them were in the ECP and three in the LCP. Look-back studies show that mutants were detected 0–20 (median 7) months ahead of the appearance of clinical resistance in 15 tested patients with acquired resistance. ABL mutations are common in Chinese imatinib-resistant CML patients and are associated with clinical resistance. Chinese patients also seem to have unique profiles in the types and frequencies of some mutants, the disease phases of patients with T315I mutation, and the frequency of mutations in CP patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C et al (2002) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346:645–652

    Article  CAS  PubMed  Google Scholar 

  2. O’Brien S, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994–1004

    Article  PubMed  Google Scholar 

  3. Branford S, Rudzki Z, Harper A, Grigg A, Taylor K, Durrant S et al (2003) Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia 17:2401–2409

    Article  CAS  PubMed  Google Scholar 

  4. Lahaye T, Riehm B, Berger U, Paschka P, Muller P, Kreil S et al (2005) Response and resistance in 300 patients with BCR–ABL positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer 103:1659–1669

    Article  PubMed  Google Scholar 

  5. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG et al (2002) Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase 2 study. Blood 99:3530–3539

    Article  CAS  PubMed  Google Scholar 

  6. Sureda A, Carrasco M, de Miguel M, Martinez JA, Conde E, Sanz MA et al (2003) Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia. Haematologica 88:1213–1220

    CAS  PubMed  Google Scholar 

  7. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J et al (2002) Multiple BCR–ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2:117–125

    Article  CAS  PubMed  Google Scholar 

  8. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al (2001) Clinical resistance to STI-571 cancer therapy caused by BCR–ABL gene mutation or amplification. Science 293:876–880

    Article  CAS  PubMed  Google Scholar 

  9. Melo JV, Chuah C (2007) Resistance to imatinib in chronic myeloid leukaemia. Cancer Lett 249:121–132

    Article  CAS  PubMed  Google Scholar 

  10. Branford S (2007) Chronic myeloid leukemia: molecular monitoring in clinical practice. Hematology Am Soc Hematol Educ Program 376–383

  11. Kim SH, Kim D, Kim DW, Goh HG, Jang SE, Lee J et al (2009) Analysis of Bcr–Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P-loop and T315I mutation is disease phase dependent. Hematol Oncol 27:190–197

    Article  CAS  PubMed  Google Scholar 

  12. Apperley J (2007) Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 8:1018–1029

    Article  CAS  PubMed  Google Scholar 

  13. Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A et al (2006) Contribution of abl kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA working party on chronic myeloid leukemia. Clin Cancer Res 12:7374–7379

    Article  CAS  PubMed  Google Scholar 

  14. Qin Y, Jiang B, Jiang Q, Jiang H, Li J, Zhang Y et al (2009) Molecular responses of late chronic phase chronic myeloid leukemia patients after achieving complete cytogenetic responses with imatinib treatment: a 6-year follow-up. Ann Hematol 88:37–41

    Article  CAS  PubMed  Google Scholar 

  15. Ernst T, Erben P, Müller MC, Paschka P, Schenk T, Hoffmann J et al (2006) Dynamics of BCR–ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib. Haematologica 93:186–192

    Article  Google Scholar 

  16. Hochhaus A, Kreil S, Corbin AS, La Rosee P, Muller MC, Lahaye T et al (2002) Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16:2190–2196

    Article  CAS  PubMed  Google Scholar 

  17. Branford S, Rudzki Z, Parkinson I, Grigg A, Taylor K, Seymour JF et al (2004) Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR–ABL kinase domain mutations. Blood 104:2926–2932

    Article  CAS  PubMed  Google Scholar 

  18. Azam M, Latek RR, Daley GQ (2003) Mechanisms of autoinhibition and STI571/imatinib resistance revealed by mutagenesis of BCR–ABL. Cell 112:831–843

    Article  CAS  PubMed  Google Scholar 

  19. Deininger M, Buchdunger E, Druker BJ (2005) The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105:2640–2653

    Article  CAS  PubMed  Google Scholar 

  20. Sorel N, Roy L, Martineau G, Guilhot F, Turhan AG, Chomel JC (2006) Sequential emergence of ABL-kinase mutations with loss of unmutated BCR–ABL allele during targeted therapies of CML. Blood 108:1782–1783

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Hematology, People’s Hospital of Peking University, 11 Xi-zhi-men South Street, Beijing, People’s Republic of China, 100044

    YaZhen Qin, ShanShan Chen, Bin Jiang, Qian Jiang, Hao Jiang, JinLan Li, LingDi Li, YueYun Lai, YanRong Liu & XiaoJun Huang

Authors
  1. YaZhen Qin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. ShanShan Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bin Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Qian Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hao Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. JinLan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. LingDi Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. YueYun Lai
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. YanRong Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. XiaoJun Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to ShanShan Chen or XiaoJun Huang.

Additional information

Grant support

This work was supported by the Program for Innovative Research Teams in University (IRT0702) from the Ministry of Education of the People’s Republic of China.

Declaration

We declare that the experiments comply with the current laws in China and that they were performed inclusive of ethics approval.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Qin, Y., Chen, S., Jiang, B. et al. Characteristics of BCR–ABL kinase domain point mutations in Chinese imatinib-resistant chronic myeloid leukemia patients. Ann Hematol 90, 47–52 (2011). https://doi.org/10.1007/s00277-010-1039-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-010-1039-5

Keywords

Search

Navigation